Nykredit A S Buys Shares of 171,773 Danaher Corporation $DHR

Nykredit A S purchased a new stake in shares of Danaher Corporation (NYSE:DHR) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 171,773 shares of the conglomerate’s stock, valued at approximately $32,719,000.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new position in Danaher during the second quarter valued at approximately $10,492,520,000. State Street Corp grew its position in Danaher by 1.7% in the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock worth $6,345,529,000 after purchasing an additional 472,608 shares during the period. Capital International Investors raised its stake in Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after buying an additional 1,487,768 shares during the last quarter. Wellington Management Group LLP raised its stake in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after buying an additional 1,542,310 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Danaher by 9.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after buying an additional 1,334,221 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Up 0.4%

Shares of DHR stock opened at $210.69 on Friday. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The firm has a fifty day moving average price of $201.50 and a 200-day moving average price of $192.17. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market cap of $148.11 billion, a price-to-earnings ratio of 37.42, a PEG ratio of 2.61 and a beta of 0.78.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the business posted $0.77 EPS. Danaher’s revenue was up 5.5% on a year-over-year basis. As a group, equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on DHR. Stifel Nicolaus dropped their price target on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. HSBC lowered their target price on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. TD Cowen dropped their target price on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Weiss Ratings upgraded Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. Finally, Guggenheim reduced their price target on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.